139. 先天性大脳白質形成不全症 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 13 / 薬物数 : 8 - (DrugBank : 4) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 3

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
Curcumin
   Inoue Ken
      2018   -   JPRN-jRCTs031180348   -
Deferiprone
   VU University Medical Center
      2022   Phase 2   EUCTR2021-000070-29-NL   Netherlands
Hucns-SC cells
   StemCells, Inc.
      2009   Phase 1   NCT01005004   United States
Hucns-SC transplant IN THE LEAD-IN phase
   StemCells, Inc.
      2011   -   NCT01391637   United States
ION356
   Ionis Pharmaceuticals, Inc.
      2024   Phase 1   NCT06150716   France;Germany;Japan;Netherlands;United States
Tiratricol
   Erasmus Medical Centre
      2016   Phase 2   EUCTR2014-000178-20-IT   Belgium;Czech Republic;France;Germany;Italy
      2016   Phase 2   EUCTR2014-000178-20-FR   Australia;Belgium;Canada;Czech Republic;France;Germany;Italy;South Africa
      2016   Phase 2   EUCTR2014-000178-20-CZ   Belgium;Czech Republic;Germany;Italy
      2015   Phase 2   EUCTR2014-000178-20-BE   Australia;Belgium;Canada;Chile;Czech Republic;France;Germany;Italy;South Africa
      -   Phase 2   EUCTR2014-000178-20-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;South Africa
   Rare Thyroid Therapeutics International AB
      2023   -   NCT05911399   United States
      2023   Phase 3   NCT05579327   Netherlands;United Kingdom;United States
Triac
   Rare Thyroid Therapeutics International AB
      2020   Phase 2   NCT02396459   Czechia;Germany;Netherlands;United States
Téatrois
   Erasmus Medical Centre
      2016   Phase 2   EUCTR2014-000178-20-IT   Belgium;Czech Republic;France;Germany;Italy
      2016   Phase 2   EUCTR2014-000178-20-FR   Australia;Belgium;Canada;Czech Republic;France;Germany;Italy;South Africa
      2016   Phase 2   EUCTR2014-000178-20-CZ   Belgium;Czech Republic;Germany;Italy
      2015   Phase 2   EUCTR2014-000178-20-BE   Australia;Belgium;Canada;Chile;Czech Republic;France;Germany;Italy;South Africa
      -   Phase 2   EUCTR2014-000178-20-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;South Africa